Claims for Patent: 8,591,895

Summary for Patent: 8,591,895

Title:	Combinations for the treatment of diseases involving cell proliferation
Abstract:	Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR00001## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
Inventor(s):	Munzert; Gerd (Ulm, DE), Steegmaier; Martin (Reutlingen, DE), Baum; Anke (Vienna, AT)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	13/342,507
Patent Claims:	1. A pharmaceutical composition comprising: (i) a compound 1 of Formula (I) ##STR01026## wherein R.sup.1, R.sup.2 which may be identical or different, denote hydrogen or optionally substituted C.sub.1-C.sub.6-alkyl, or R.sup.1 and R.sup.2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R.sup.3 denotes hydrogen or a group selected from among optionally substituted C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl, C.sub.2-C.sub.12-alkynyl and C.sub.6-C.sub.14-aryl, or a group selected from among optionally substituted and/or bridged C.sub.3-C.sub.12-cycloalkyl, C.sub.3-C.sub.12-cycloalkenyl, C.sub.7-C.sub.12-polycycloalkyl, C.sub.7-C.sub.12-polycycloalkenyl, C.sub.5-C.sub.12-spirocycloalkyl, C.sub.3-C.sub.12-heterocycloalkyl which contains 1 to 2 heteroatoms, and C.sub.3-C.sub.12-heterocycloalkenyl which contains 1 to 2 heteroatoms, or R.sup.1 and R.sup.3 or R.sup.2 and R.sup.3 together denote a saturated or unsaturated C.sub.3-C.sub.4-alkyl bridge which may contain 1 heteroatom, R.sup.4 denotes a group selected from among hydrogen, --CN, hydroxy, --NR.sub.6R.sub.7 and halogen, or a group selected from among optionally substituted C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.1-C.sub.5-alkyloxy, C.sub.2-C.sub.5-alkenyloxy, C.sub.2-C.sub.5-alkynyloxy, C.sub.1-C.sub.6-alkylthio, C.sub.1-C.sub.6-alkylsulphoxo and C.sub.1 -C.sub.6-alkylsulphonyl, L denotes a linker selected from among optionally substituted C.sub.2-C.sub.10-alkyl, C.sub.2-C.sub.10-alkenyl, C.sub.6-C.sub.14-aryl, --C.sub.2-C.sub.4-alkyl-C.sub.6-C.sub.14-aryl, --C.sub.6-C.sub.14-aryl-C.sub.1-C.sub.4-alkyl, optionally bridged C.sub.3-C.sub.12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms, n denotes 0 or 1 m denotes 1 or 2 R.sup.5 denotes a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R.sup.8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, --NR.sup.8R.sup.9 and azacycloheptyl, R.sup.6, R.sup.7 which may be identical or different, denote hydrogen or C.sub.1-C.sub.4-alkyl, and R.sup.8, R.sup.9 denote unsubstituted nitrogen substituents at R.sup.5, which may be identical or different, denote either hydrogen or a group selected from among C.sub.1-C.sub.6-alkyl, --C.sub.1-C.sub.4-alkyl-C.sub.3-C.sub.10-cycloalkyl, C.sub.3-C.sub.10-cycloalkyl, C.sub.6-C.sub.14-aryl, --C.sub.1-C.sub.4-alkyl-C.sub.6-C.sub.14-aryl, pyranyl, pyridinyl, pyrimidinyl, C.sub.1-C.sub.4-alkyloxycarbonyl, C.sub.6-C.sub.14 -arylcarbonyl, C.sub.1-C.sub.4-alkylcarbonyl, C.sub.6-C.sub.14-arylmethyloxycarbonyl, C.sub.6-C.sub.14-arylsulphonyl, C.sub.1-C.sub.4-alkylsulphonyl- and C.sub.6-C.sub.14-aryl-C.sub.1-C.sub.4-alkylsulphonyl-, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts; and (ii) at least one further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2, which is selected from the group consisting of the di-maleic acid salt of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N -dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)- -quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu- ten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 3-Z-[1-(4-(N-((4-methyl -piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methyl- ene]-6-methoxycarbonyl-2-indolinone, the monoethanesulfonate salt of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, 3-Z-[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methyle- ne]-6-fluoro-2-indolinone, irinotecan, topotecan, oxaliplatin, docetaxel, paclitaxel, gemcitabine, pemetrexed, cisplatin, carboplatin, bevacizumab, cetuximab, gefitinib and erlotinib, or a tautomer, stereoisomer or a pharmaceutically acceptable salt thereof; optionally in combination with one or more pharmaceutically acceptable excipients, and optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy, in the form of a combined preparation for simultaneous, separate or sequential administration. 2. The pharmaceutical composition according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the quinazoline derivative 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical combination according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the di-maleic acid salt of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N -dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)- -quinazoline, or 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu- ten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, or the tautomers, stereoisomers or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical combination according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu- ten-1-yl]amino}-7-[(S) -(tetrahydrofuran-3-yl)oxy]-quinazoline , or the tautomers, stereoisomers or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical combination according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 3-Z -[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anil- ino)-1-phenyl -methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof. 6. The pharmaceutical combination according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the monoethanesulfonate salt of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N -methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinon- e. 7. The pharmaceutical combination according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 3-Z -[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]- -6-fluoro-2-indolinone, or a polymorph, metabolite or pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition according to claim 1, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is selected from the group consisting of irinotecan, topotecan, oxaliplatin, docetaxel, paclitaxel, gemcitabine, pemetrexed, cisplatin, carboplatin, bevacizumab, cetuximab, gefitinib, or erlotinib. 9. The pharmaceutical composition according to claim 1, wherein the compound 1 is: TABLE-US-00003 ##STR01027## Config. R.sup.1 or R.sup.1 R.sup.2 R.sup.2 R.sup.3 R.sup.4 L.sub.n--R.sup.5.sub.m H ##STR01028## R ##STR01029## ##STR01030## ##STR01031## wherein the abbreviations X.sub.2, X.sub.3, X.sub.4 and X.sub.5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and L-R.sup.5. 10. The pharmaceutical composition according to claim 1, wherein the compound 1 is: TABLE-US-00004 ##STR01032## Config. R.sup.1 or R.sup.1 R.sup.2 R.sup.2 R.sup.3 R.sup.4 L.sub.n--R.sup.5.sub.m H ##STR01033## R ##STR01034## ##STR01035## ##STR01036## wherein the abbreviations X.sub.2, X.sub.3, X.sub.4 and X.sub.5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and L-R.sup.5. 11. The pharmaceutical composition according to claim 1, wherein the compound 1 is selected from the group consisting of the compounds of formula shown in the following Table: TABLE-US-00005 27 H ##STR01037## R ##STR01038## ##STR01039## ##STR01040## 44 H ##STR01041## R ##STR01042## H ##STR01043## 46 H ##STR01044## R ##STR01045## ##STR01046## ##STR01047## 55 H ##STR01048## R ##STR01049## ##STR01050## ##STR01051## 58 H ##STR01052## R ##STR01053## ##STR01054## ##STR01055## 102 H ##STR01056## R ##STR01057## ##STR01058## ##STR01059## 103 H ##STR01060## R ##STR01061## ##STR01062## ##STR01063## 105 H ##STR01064## R ##STR01065## ##STR01066## ##STR01067## 110 H ##STR01068## R ##STR01069## ##STR01070## ##STR01071## 115 H ##STR01072## R ##STR01073## ##STR01074## ##STR01075## 133 H ##STR01076## R ##STR01077## ##STR01078## ##STR01079## 134 H ##STR01080## R ##STR01081## ##STR01082## ##STR01083## 234 H ##STR01084## R ##STR01085## ##STR01086## ##STR01087## 240 H ##STR01088## R ##STR01089## ##STR01090## ##STR01091## wherein the abbreviations X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and L-R.sup.5. 12. The pharmaceutical composition according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the quinazoline derivative 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or a pharmaceutically acceptable salt thereof. 13. The pharmaceutical combination according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the di-maleic acid salt of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N -dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)- -quinazoline, or 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu- ten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, or the tautomers, stereoisomers or a pharmaceutically acceptable salt thereof. 14. The pharmaceutical combination according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu- ten-1-yl]amino}-7-[(S) -(tetrahydrofuran-3-yl)oxy]-quinazoline , or the tautomers, stereoisomers or a pharmaceutically acceptable salt thereof. 15. The pharmaceutical combination according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 3-Z -[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anil- ino)-1-phenyl -methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof. 16. The pharmaceutical combination according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is the monoethanesulfonate salt of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N -methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinon- e. 17. The pharmaceutical combination according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is 3-Z -[1-(4-dimethylaminomethylanilino)-1-(4-(2-carboxyethyl)phenyl)methylene]- -6-fluoro-2-indolinone, or a pharmaceutically acceptable salt thereof. 18. The pharmaceutical composition according to claim 11, wherein the further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent 2 is selected from the group consisting of irinotecan, topotecan, oxaliplatin, docetaxel, paclitaxel, gemcitabine, pemetrexed, cisplatin, carboplatin, bevacizumab, cetuximab, gefitinib, or erlotinib.

Details for Patent 8,591,895

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2024-08-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2024-08-14
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-08-14